Modig Berndt sold $80K of PHVS

Modig Berndt (Chief Executive Officer) sold 2,292 shares of Pharvaris N.V. (PHVS) at $34.97 on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Modig Berndt
Published Jul 15, 2026, 5:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 5:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
high confidence
Mentioned
$PHVS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The CEO’s open-market sale is disclosed with a stated pre-arranged 10b5-1 plan, which generally lowers the probability of a strong negative fundamental interpretation.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new business or financial datapoint in the text.

03

What to watch

The article does not disclose any concurrent operational updates, guidance changes, or clinical/regulatory milestones, so the trading signal is limited to sentiment.

Relevance 2/10Novelty 3/10Timing: today’s SEC Form 4 filing (filed 2026-07-15) for a 2026-07-13 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralHigh confidence
Context

Pharvaris CEO Modig Berndt sold 2,292 shares in an open-market transaction on 2026-07-13 at $34.9714, per Form 4.

Expected impact

Likely minimal immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing specifies a Rule 10b5-1 pre-arranged plan and an open-market sale, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification or tax planning and may not reflect bearish expectations, especially under a 10b5-1 plan.

Key entities

  • Pharvaris N.V.

    Company whose CEO insider sale is disclosed on SEC Form 4.

  • Modig Berndt

    CEO and director who executed the reported sale.

  • Rule 10b5-1 plan

    Pre-arranged plan cited as Yes, reducing discretionary-signal strength.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.